Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery, at a moderate or advanced stage, confirmed either by a biopsy or by clinical assessment
• People who have at least one measurable liver tumor that has not yet been treated
• People whose liver tumors could be treated with 1 or 2 sessions of a type of radiation therapy delivered through blood vessels (SIRT)
• People with a liver function score (Child-Pugh) of 5 to 7, indicating reasonably preserved liver function
• People who are fully active or have only minor limitations in daily activity (ECOG performance status of 0 or 1)
• People with a life expectancy of at least 3 months
• People with active hepatitis B, provided they are receiving antiviral treatment that has brought the virus to a sufficiently low level in the blood
• People with hepatitis C, provided they have completed their hepatitis C treatment

Who may not be able to join:

• People whose tumour takes up 70% or more of the liver
• People whose cancer has spread into the main portal vein or into both of its major branches
• People whose cancer has invaded the large vein that carries blood to the heart (vena cava)
• People whose cancer has spread to the brain or central nervous system
• People whose cancer has spread to major airways or large blood vessels
• People who have previously received certain liver-directed treatments (such as HAIC, TACE, or TAE), radiotherapy, or any systemic therapy for their liver cancer
• People who have had an organ or cell transplant at any point
• People with a history of bleeding from swollen veins in the food pipe or stomach (varices)
• People with signs of significant liver dysfunction, such as fluid build-up in the abdomen, swollen varices in the food pipe or stomach, or confusion caused by liver failure
• People with signs of high blood pressure in the portal vein with a high risk of bleeding
• People who have used medications that suppress the immune system within 4 weeks before the first dose of study treatment
• People who have had major surgery, or who have a wound, ulcer, or fracture that has not fully healed, within 4 weeks before the first dose of study treatment
• People who have had a life-threatening bleeding event in the 3 months before joining, including those who needed a blood transfusion, surgery, targeted treatment for bleeding, or ongoing medication for it
• People with low white blood cell counts (below 3×10⁹/L) or low platelet counts (below 50×10⁹/L)
• People whose blood clotting time (prothrombin time) is prolonged by more than 4 seconds
• People with severe dysfunction of the heart, lungs, or kidneys
• People with a history of another type of cancer
• People infected with both hepatitis B and hepatitis C at the same time
• People living with HIV
• People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.